Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | November 11, 2016 |
| Target | SERI Surgical Scaffold |
| Sector | Life Science |
| Buyer(s) | Sofregen Medical |
| Sellers(s) | Allergan |
| Deal Type | Divestiture |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
Sofregen Medical is a provider of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. Sofregen Medical was founded in 2014 and is based in Framingham, Massachusetts.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: New Jersey | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2016 | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Life Science |
| Employees | 31,200 |
| Revenue | 15.8B USD (2018) |
Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.
| Deal Context for Seller | # |
|---|---|
| Overall | 7 of 9 |
| Sector: Life Science | 5 of 7 |
| Type: Divestiture | 7 of 9 |
| State: New Jersey | 3 of 4 |
| Country: United States | 7 of 8 |
| Year: 2016 | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-27 |
Motus Therapeutics
Boston, United States Motus Therapeutics, Inc. is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-11-22 |
Chase Pharmaceuticals
Washington, District of Columbia, United States Chase Pharmaceuticals Corporation, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase's development program, if successful, will profoundly improve the symptomatic treatment of Alzheimer's disease. |
Buy | $125M |
